An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab

Journal of Drugs in Dermatology

Volumn 10, Issue 4, 2011, Pages 396-402

  Vender, Ronald ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ALOPECIA; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DERMATOLOGY QUALITY OF LIFE INDEX; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FEMALE PATTERN ALOPECIA; HUMAN; MALE; OPEN STUDY; PHYSICIAN GLOBAL ASSESSMENT; PROSPECTIVE STUDY; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SUBJECT GLOBAL ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL PHARYNGITIS; DRUG ANTAGONISM; HOSPITALIZATION; MIDDLE AGED; PILOT STUDY; PSORIASIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052883932     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Martyn-Simmons CL, Green L, Ash G, et al. Adalimumab for psoriasis patients who are non-responders to etanercept: Open-label prospective evaluation. J Eur Acad Derm Vener. 2009;23(12);1394-1397.
2. Pitarch JL, Sanchez-Carazo JL, Mahiques L, et al. Treatment of psoriasis with adalimumab. Clin Exp Dermatol. 2007;32(1):18-22. (Pubitemid 46006359)
3. Van L, Modi SV, Yang DJ, et al. Sustained efficacy and safety of adalimumab in psoriasis treatment: A retrospective study of 49 patients with and without a history of TNF-α Antagonist Treatment. Arch Dermatol. 2008;144:804-806. (Pubitemid 351846889)
4. Finlay AY, Khan GK. DLQI-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-216.
5. Hongbo Y, Thomas CL, Harrison MA, et al. Translating the Science of Quality of Life into Practice: What Do Dermatology Life Quality Index Scores Mean? J Inv Derm. 2005;125:659-664.
6. Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: Assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007;156(5):945-50. (Pubitemid 46642856)
7. Pelivani N, Hassan AS, Braathen LR, et al. Alopecia Areata Universalis Elicited during Treatment with Adalimumab. Dermatology. 2008;216:320-323. (Pubitemid 351630097)
8. Bartels NG, Lee H, Worm M; et al. Development of Alopecia Areata Universalis in a Patient Receiving Adalimumab. Arch Dermatol. 2006;142(12):1654-1653.
9. Posten W, Swan J. Recurrence of Alopecia Areata in a Patient Receiving Etanercept Injections. Arch Dermatol. 2005;141(6):759-760. (Pubitemid 41001077)
10. Strober BE, Siu K, Alexis AF, et al. Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study. J Amer Acad Derm. 2005;52(6):1082-1084. (Pubitemid 40732553)
11. Shukla R, Vender R, Pharmacology and Pharmacokinetics of Tumour Necrosis Factor Inhibitors. In: Weinberg JM, Buchholz R, eds. Milestones in Drug Therapy. TNF-alpha Inhibitors. Birkhäuser; 2006. (IX) 23-44.
12. Ravindran V, Scott DL, Choy EH. Extended report: A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis. 2008;67:855-859. (Pubitemid 351829388)
13. Enbrel [Product Monograph] Thousand Oaks CA USA: Immunex Corp; Oct 6, 2009.
14. Humira [Product Monograph] St-Laurent (QC) Canada: Abbott Laboratories Ltd; Dec16, 2009.
15. Remicade [Product Monograph] Malvern PA USA: Centocor Inc; Mar 9, 2009.
16. Noiles K, Vender R. Biologic Survival. J Drugs Derm. 2009;8(4):329-333.
17. Lecluse LA, Driessen RJ, Spuls PI, et al. Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis. Arch Dermatol. 2010;146(2):127-132.